These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39049789)

  • 21. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably.
    Lindgren AC; Hagenäs L; Müller J; Blichfeldt S; Rosenborg M; Brismar T; Ritzén EM
    Acta Paediatr; 1998 Jan; 87(1):28-31. PubMed ID: 9510443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
    Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC;
    J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
    Corripio R; Tubau C; Calvo L; Brun C; Capdevila N; Larramona H; Gabau E
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):879-884. PubMed ID: 31271556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group.
    Lindgren AC; Ritzén EM
    Acta Paediatr Suppl; 1999 Dec; 88(433):109-11. PubMed ID: 10626558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of growth hormone treatment in children with Prader-Willi syndrome over a 30-year period: a single tertiary center experience.
    Gamage DS; Ambler G; Chan A; Srinivasan S; Maguire AM; Cho YH
    J Pediatr Endocrinol Metab; 2024 Aug; 37(8):680-685. PubMed ID: 39089289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased IGFBP Proteolysis, IGF-I Bioavailability, and Pappalysin Levels in Children With Prader-Willi Syndrome.
    Barrios V; Martín-Rivada Á; Martos-Moreno GÁ; Canelles S; Moreno-Macián F; De Mingo-Alemany C; Delvecchio M; Pajno R; Fintini D; Chowen JA; Argente J
    J Clin Endocrinol Metab; 2024 Aug; 109(9):e1776-e1786. PubMed ID: 38141219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid function in children with Prader-Willi syndrome in Southern China: a single-center retrospective case series.
    Huang X; Yin X; Wu D; Cai Y; Li X; Zhang W; Zeng C; Mao X; Liu L
    BMC Pediatr; 2022 Apr; 22(1):234. PubMed ID: 35488223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader-Willi syndrome.
    Trueba-Timmermans DJ; Grootjen LN; Juriaans AF; Mahabier EF; Kerkhof GF; Rings EHHM; Hokken-Koelega ACS
    Eur J Endocrinol; 2023 Jul; 189(1):132-139. PubMed ID: 37440711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of 8 years of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
    Grootjen LN; Rutges JPHJ; Damen L; Donze SH; Juriaans AF; Kerkhof GF; Hokken-Koelega ACS
    Eur J Endocrinol; 2021 May; 185(1):47-55. PubMed ID: 33886496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of recombinant human growth hormone on thyroid function in patients with growth hormone deficiency].
    Tang D; Wang J; Wu C
    Zhonghua Nei Ke Za Zhi; 1997 Nov; 36(11):754-8. PubMed ID: 10451949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
    de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome.
    Rigamonti AE; Crinò A; Bocchini S; Convertino A; Bidlingmaier M; Haenelt M; Tamini S; Cella SG; Grugni G; Sartorio A
    Growth Horm IGF Res; 2018 Apr; 39():13-18. PubMed ID: 29217318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IGF-1 Levels, Complex Formation, and IGF Bioactivity in Growth Hormone-Treated Children With Prader-Willi Syndrome.
    Bakker NE; van Doorn J; Renes JS; Donker GH; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3041-9. PubMed ID: 26050733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial and 8-year longitudinal study.
    Lo ST; Siemensma EP; Festen DA; Collin PJ; Hokken-Koelega AC
    Eur Child Adolesc Psychiatry; 2015 Sep; 24(9):1091-101. PubMed ID: 25522840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; de Klerk LW; Festen DA; Duivenvoorden HJ; Otten BJ; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1274-80. PubMed ID: 19158197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome.
    Grugni G; Crinò A; Pagani S; Meazza C; Buzi F; De Toni T; Gargantini L; Pilotta A; Pozzan GB; Radetti G; Ragusa L; Salvatoni A; Sartorio A; Bozzola M;
    J Pediatr Endocrinol Metab; 2011; 24(7-8):477-81. PubMed ID: 21932585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial Effect of Growth Hormone Treatment on Health-Related Quality of Life in Children with Prader-Willi Syndrome: A Randomized Controlled Trial and Longitudinal Study.
    Bakker NE; Siemensma EP; van Rijn M; Festen DA; Hokken-Koelega AC
    Horm Res Paediatr; 2015; 84(4):231-9. PubMed ID: 26279206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.
    Oto Y; Tanaka Y; Abe Y; Obata K; Tsuchiya T; Yoshino A; Murakami N; Nagai T
    Am J Med Genet A; 2014 Mar; 164A(3):671-5. PubMed ID: 24443368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.